Why Jaguar Health Stock Is Crashing
Portfolio Pulse from Erica Kollmann
Jaguar Health, Inc. (NASDAQ:JAGX) shares are plummeting after the company announced that its phase 3 OnTarget trial for crofelemer did not meet its primary endpoint. The trial aimed to address diarrhea in cancer patients undergoing therapy but failed due to the heterogeneous nature of the patients. Despite this, some benefits were observed in patients with breast and respiratory cancers. The stock is experiencing heavy trading volume, with shares down 56.2% at $1.87.
July 23, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Jaguar Health's phase 3 OnTarget trial for crofelemer did not meet its primary endpoint, causing shares to drop 56.2%. The trial's failure is attributed to the heterogeneous nature of the patients. Despite this, some benefits were noted in patients with breast and respiratory cancers.
The failure of the phase 3 OnTarget trial is a significant setback for Jaguar Health, leading to a sharp decline in stock price. The heavy trading volume indicates strong market reaction. Although some benefits were observed in specific cancer types, the overall trial failure overshadows these findings.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100